Cancer Therapy

Virulizin receives patent protection

Published in Cancer Weekly, December 17th, 2002

Lorus Therapeutics, Inc., announced that it has received notice from the United States Patent and Trademark Office (USPTO) of the allowance of a patent protecting the company's intellectual property for its lead anticancer drug, Virulizin.

It is currently in a phase III clinical trial in the United States for the treatment of advanced pancreatic cancer and has received approval in Mexico for the treatment of malignant melanoma.

This marks the second U.S. patent for Virulizin, with the first being issued in 2000 to protect the only known production process of the drug. This recent patent allowance protects the Virulizin invention as it relates to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry